CD47 and neoplasm: designed LNPs to engage tumor‐associated MDSCs and glioblastoma cells via anti‐CD47/PD‐L1 dual ligation (Figure 4F).[62] The findings of the study showed that the simultaneous blockage of CD47 and PD‐L1 increased MDSC phagocytic activity (Figure 4G).